Kit d'Amplification d'ARN SeqPlex, à utiliser avec les technologies de séquençage à haut débit

Code: seqr-10rxn D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

SeqPlex RNA Amplification Kit has been used to amplify poly(A)-selected RNA.

Features and Benefits

Low quantities o...


en savoir plus

Votre prix
$1,154.24 10RXN

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

SeqPlex RNA Amplification Kit has been used to amplify poly(A)-selected RNA.

Features and Benefits

Low quantities of total RNA random priming technology amplifies fragmented or intact RNA from all sources including FFPE and RIP. Semi-degenerate library primer design for more complete transcriptome coverage and efficient priming. No need to fragment DNA before sequencing. Amplifies ds-cDNA in 8 hours or less. Compatible with all next generation sequencing platforms except Pacific Bioscience.

General description

The SeqPlex RNA Amplification Kit for whole transcriptome amplification (WTA) is designed to facilitate next-generation sequencing (NGS) from small quantities or from degraded/highly fragmented RNA (e.g. RNA from formalin-fixed paraffin-embedded (FFPE) tissue samples). The SeqPlex kit allows the user to pre-amplify these and other small quantity/highly fragmented RNA samples for input into a NGS workflow. It also facilitates the amplification of non-polyA tailed RNA isolated from tissue, cultured cells, formalin-fixed samples, or serum while maintaining patterns of differential expression found in the unamplified sample.

Legal Information

SeqPlex is a trademark of Sigma-Aldrich Co. LLC

Other Notes

SEQR-500RXN is manufactured on-demand. Contact us for more information.

Quality Level200
shipped inwet ice
storage temp.−20°C
technique(s)whole genome amplification: suitable
Code
Description
Unité de vente
Prix annoncé
Qté
SEQR-500RXN
Unité:500RXN
Prix annoncé: $26,495.92
Source:Prix annoncé
SEQR-50RXN
Unité:EACH
Prix annoncé: $5,025.09
Source:Prix annoncé
Ce produit répond aux critères suivants: